Cytogen's ProstaScint enters IMRT (intensity modulated radiation therapy) trials:
This article was originally published in Clinica
Executive Summary
A phase I/II clinical study is underway to evaluate Cytogen's ProstaScint imaging agent in improving the precision of intensity modulated radiation therapy (IMRT) for prostate cancer. ProstaScint, a radiolabelled monoclonal antibody, is injected intravenously into the patient where it binds to a highly expressed marker for prostate cancer. The enhanced images will allow for radiation to be more highly focused on the tumour, reducing damage to the surrounding tissue, said the Princeton, New Jersey firm.